Design Therapeutics, Inc. shares rise 3.98% intraday after Twist Bioscience collaboration for novel antibody-drug conjugates.

martes, 2 de septiembre de 2025, 2:19 pm ET1 min de lectura
DSGN--
Design Therapeutics, Inc. rose 3.98% intraday, with the company's collaboration with Twist Bioscience Corporation (NASDAQ: TWST) to develop novel antibody-drug conjugates for various cancer types. Twist Bioscience's high throughput expertise in novel binder discovery services and high throughput screening capabilities will support Synthetic Design Lab’s development of novel engineered therapeutics.

Design Therapeutics, Inc. shares rise 3.98% intraday after Twist Bioscience collaboration for novel antibody-drug conjugates.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios